Glimpses of the near future: a new generation of mTOR inhibitors.

[1]  B. Jham,et al.  The Akt/mTOR pathway is activated in verrucous carcinoma of the oral cavity. , 2016, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[2]  G. De Luca Canto,et al.  mTOR pathway protein immunoexpression as a prognostic factor for survival in head and neck cancer patients: a systematic review and meta-analysis. , 2016, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[3]  Elisa de Stanchina,et al.  Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor , 2016, Nature.

[4]  Xian-hui He,et al.  Discovering new mTOR inhibitors for cancer treatment through virtual screening methods and in vitro assays , 2016, Scientific Reports.

[5]  C. Van Waes,et al.  The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies. , 2015, Oral diseases.

[6]  L. Mell,et al.  Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck. , 2015, Oral oncology.

[7]  G. Mills,et al.  A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma , 2014, Molecular Cancer Therapeutics.

[8]  A Vacca,et al.  Therapeutic targeting of the mTOR‐signalling pathway in cancer: benefits and limitations , 2014, British journal of pharmacology.

[9]  Jiri Polivka,et al.  Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. , 2014, Pharmacology & therapeutics.

[10]  J. Tabernero,et al.  Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors , 2014, Molecular Cancer Therapeutics.

[11]  J. Gutkind,et al.  Exploiting the head and neck cancer oncogenome: widespread PI3K-mTOR pathway alterations and novel molecular targets. , 2013, Cancer discovery.

[12]  S. Warnakulasuriya,et al.  Phosphorylated mammalian target of rapamycin is associated with an adverse outcome in oral squamous cell carcinoma. , 2013, Oral surgery, oral medicine, oral pathology and oral radiology.

[13]  S. George,et al.  A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. , 2013, Oral oncology.